BMO Capital raised the firm’s price target on BridgeBio (BBIO) to $42 from $37 and keeps a Market Perform rating on the shares. The firm anticipates Attruby’s U.S. sales in Q2 to be $77M-$89M, reflecting 110%-145% sequential growth and 20%-40% revenues above consensus, helping to drive 5%-15% upside in BridgeBio shares, the analyst tells investors in a research note.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- Hold Rating for BridgeBio Pharma Amid Competitive Pressures and Uncertain Long-term Outlook
- BridgeBio Pharma: Strong Launch Momentum and Promising Pipeline Drive Buy Rating
- BridgeBio presents data from ATTRibute-CM
- BridgeBio Pharma: Promising Outlook with Strong Execution and Growth Potential
- BridgeBio announces first participant dosed with acoramidis in ACT-EARLY